NEUBASE THERAPEUTICS
NeuBase has developed a modular antisense technology platform with the capability to address any rare genetic disease caused by mutant proteins with a single, cohesive approach. NeuBase's platform improves upon gene silencing therapies by combining the advantages of synthetic approaches with the precision of antisense technologies. Newbies plans to use its unparalleled antisense platform to address both repeat expansion disorders, with an initial focus on Huntington's Disease and Myotonic Dystrophy, and dominant genetic disorders.
NEUBASE THERAPEUTICS
Industry:
Biotechnology Medical Therapeutics
Founded:
2009-08-04
Address:
Pittsburgh, Pennsylvania, United States
Country:
United States
Website Url:
http://www.neubasetherapeutics.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
9 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics Wordpress Plugins
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Borea Therapeutics
Borea Therapeutics is advancing a new generation of gene therapies that would enable the targeting of specific tissues and cells.
Eureka Therapeutics
Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-29 | NeuBase Therapeutics Announces Promotion of Dr. William Mann to President and COO |
| 2021-09-14 | NeuBase Therapeutics Appoints Anthony Rossomando, Ph.D. as Chief Technology Officer |
| 2020-08-03 | NeuBase Therapeutics hires COO |
Official Site Inspections
http://www.neubasetherapeutics.com Semrush global rank: 2.14 M Semrush visits lastest month: 9.37 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "NeuBase Therapeutics"
NeuBase Therapeutics Reports Business Update and Financial …
Aug 11, 2022 · Committed to support the Myotonic Dystrophy Clinical Research Network, the world’s largest patient organization focused solely on myotonic dystrophy. The Company …See details»
NeuBase Therapeutics, Inc. (NBSE)
NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as …See details»
NeuBase Therapeutics Reports Business Update and Financial …
Dec 23, 2021 · To achieve this goal, we designed, built, and validated a new precision genetic medicines platform technology that can uniquely drug the double-stranded human genome …See details»
NeuBase Therapeutics - Crunchbase Company Profile & Funding
NeuBase Therapeutics is a pre-clinical stage biopharmaceutical company that develops gene silencing therapies with its synthetic antisense oligonucleotides. It also provides a platform that …See details»
NeuBase Therapeutics Announces Strategic Restructuring Focused …
PITTSBURGH, Oct. 14, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today announced plans to restructure the Company to …See details»
NeuBase Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Nov 1, 2024 · Free Whitepaper Cell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way …See details»
NeuBase Therapeutics Reports Business Update and Financial …
PITTSBURGH, Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the …See details»
NeuBase Announces Closing of $5 Million Concurrent
PITTSBURGH, June 30, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ …See details»
NeuBase Announces Formation of Gene Editing Advisory Board
May 16, 2023 · Our technology leverages the differentiated gene editing capabilities of our PATrOL™ platform, which promises the unique ability to achieve precise repair of a diverse …See details»
NeuBase Therapeutics Announces Strategic Restructuring Focused …
PITTSBURGH, Oct. 14, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today announced plans to restructure the Company to …See details»
NeuBase Therapeutics sets third vote to dissolve company, but …
Jun 4, 2024 · NeuBase (Nasdaq: NBSE) set a June 26 date for a special shareholder meeting to approve the company’s dissolution plan the board said was the best alternative moving …See details»
NeuBase Therapeutics to Explore Strategic Alternatives - Yahoo …
PITTSBURGH, Aug. 03, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ …See details»
NeuBase Therapeutics Announces Acquisition of Gene Modulating ...
Jan 28, 2021 · Consolidates new peptide nucleic acid technology into NeuBase’s PATrOL™ platform. Extends the ability of NeuBase’s existing technology to directly modulate the human …See details»
NeuBase - Overview, News & Similar companies | ZoomInfo.com
Apr 5, 2024 · View NeuBase (www.neubasetherapeutics.com) location in Pennsylvania, United States , revenue, industry and description. Find related and similar companies as well as …See details»
NeuBase Therapeutics - VentureRadar
Website: https://www.neubasetherapeutics.com/ Develops designer PATrOL™ therapies using a proprietary drug scaffold to address genetic diseases, focusing on neurological, …See details»
NeuBase Therapeutics Announces Strategic Restructuring
PITTSBURGH, Oct. 14, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today announced plans to restructure the Company to …See details»
NeuBase Therapeutics Presents New Preclinical Data at MDA
Mar 13, 2022 · NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines that Drug the Genome™.See details»
NeuBase Therapeutics Announces Gene Editing Research …
Oct 21, 2022 · NeuBase’s PATrOL™ platform is a PNA-based technology designed to address disease at the root of causality to help patients with rare and common diseases by editing, …See details»
NeuBase Therapeutics Announces Acquisition of Gene Modulating ...
PITTSBURGH, Jan. 28, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic …See details»
NeuBase Therapeutics Announces Positive, Preclinical Data …
PITTSBURGH, March 31, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation …See details»